NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study
Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study
CompletedPhase 2
Sponsor: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Conditions: Pain
Interventions: 440 mg naproxen sodium with 1000 mg acetaminophen, 220 mg naproxen sodium with 650 mg acetaminophen, 10 mg hydrocodone + 650 mg acetaminophen, 440 mg naproxen sodium, Placebo tablet
Countries: United States
Study assessing efficacy and safety of concomitantly dosed naproxen sodium with acetaminophen, compared with naproxen sodium, hydrocodone/acetaminophen and Placebo in a postoperative dental pain.
Eligibility overview
Sex: ALL
Age: 17 Years to 50 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Eligibility criteria
Inclusion Criteria: 1. Males of females 17-50 years old 2. Weigh 100 pounds or greater and have a body mass index (BMI) of 18.5 to 35 (inclusive) at screening 3. Surgical removal of up to four third molars, of which, two must be mandibular impactions 4. Meets requirements for post -surgical pain level 5. Females of childbearing potential and males agree to contraceptive requirements of study 6. Have a negative urine drug screen at screening, and on day of surgical procedure Exclusion Criteria: 1. Pregnant female, breastfeeding, trying to become pregnant or male with pregnant partner or partner currently trying to become pregnant 2. Have known allergy or hypersensitivity to naproxen or other NSAIDS, including aspirin, or to acetaminophen, tramadol, hydrocodone or other opioids 3. Not able to swallow large tablets or capsules 4. History of any condition (s) in investigator's opinion, may jeopardize subject safety, well-being and integrity of study 5. Use analgesics 5 or more times per week 6. History of chronic tranquilizer use, heavy drinking, substance abuse as judged by investigator site staff within last 5 years 7. Use of immunosuppressive drugs within 2 weeks of screening 8. History of peptic ulcer disease or gastrointestinal bleeding in the last two years or hematologic bleeding
Locations (1)
- Salt Lake City, Utah, United States